Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 298.25mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy);   - powder for injection - 250 mg - active: ceftriaxone sodium 298.25mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy)  

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 596.5mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd);   - powder for injection - 500 mg - active: ceftriaxone sodium 596.5mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd)  

États-Unis - anglais - NLM (National Library of Medicine)

a-s medication solutions - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 500 mg - before instituting treatment with ceftriaxone for injection, usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused

Australie - anglais - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ceftriaxone -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ceftriaxone -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ceftriaxone -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftriaxone sodium, quantity: 2386.6 mg - injection, powder for - excipient ingredients: - indications: treatment for the following infections when caused by susceptible aerobic organisims: 1 lower respiratory tract infections. caused by strep.pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph.aureus, h.influenzae, h.parainfluenzae, klebsiella sp. (including k.pneumoniae). e.coli, e.aerogenes, p.mirabilis and serratia marcescens. 2 skin and skin structure infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, streptococcus group g, strep.pyogenes, strep.virdans, streptococcus sp. (excluding enterococci), peptostreptococcus sp., e.coli, e.cloacae, klebsiella sp. (including k.pneumoniae and k.oxytoca), p.mirabilis, m.morganii and s.marcescens. 3 urinary tract infections (complicated and uncomplicated). caused by e.coli, p.mirabilis, p.vulgaris, m.morganii and klebsiella sp. (including k.pneumoniea). 4 uncomplicated gonorrhoea (cervical/urethral and rectal). caused by n.gonorrhoeae, including both penicillinase and nonpenicillinase producing strains. 5 bacterial septicaemia. caused by strep.pneumoniae, e.coli and h.influenzae. 6 bone infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, strep.pneumoniae, streptococcus sp. (excluding enterocci), e.coli, enterobacter sp., pmirabilis and k.pneumoniae. 7 joint infection. caused by methicillin sensitive staph.aureus, strep.pneumoniae, streptococcus sp. (excluding enterococci), e.coli, p.mirabilis, k.pneumoniae and enterobacter sp. 8 menigitis. the initial treatment, as a single agent, of menigitis in children and immunocompetent adults when presumed or proven to be caused by h.influenzae type b, n.menigitidis, strep.pneumoniae or enterobacteriaceae pending culture and sensitivity results. 9 surgical prophylaxis. the preoperative administration of a single 1g dose of ceftriaxone may reduce the incidence of postoperative infections in patients_undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures whic are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. 10susceptibility testing. before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its sussceptibility ot the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftriaxone sodium, quantity: 1193.3 mg - injection, powder for - excipient ingredients: - indications: treatment for the following infections when caused by susceptible aerobic organisms: 1 lower respiratory tract infections. caused by strep.pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph.aureus, h.incluenzae, h.parain fluenzae, klebsiella sp. (including k.pneumoniae). e.coli, e. aerogenes, p.mirabilis and serratia marcescens. 2 skin and skin structure infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, streptococcus group g, strep.pyogenes, strep.viridans, streptococcus sp. (excluding enterococci), peptostreptococcus sp.,_(including k.pneumoniae and k.oxytoca), p.mirabilis, m.morganii and s.marcescens. 3 urinary tract infections (complicated and uncomplicated). caused by e.coli, p.mirabilis, p.vulgaris, m.morganii and klebsiella sp. (including k.pneumoniae). uncomplicated gonorrhoea (cervical/urethral and rectal) caused by n.gonorrhoeae, including both penicillinase and nonpenicillinase producing strains. 5 bacterial septicaemia. caused by strep.pneumoniae, e.coli and h.influenzae. 6 bone infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, strep.pneumoniae., streptococcus sp._ 7 joint infections. caused by methicillin sensitive staph.aureus, strep.pneumoniae, streptococcus sp. (excluding enterococci), e.coli, p.mirabilis. k.pneumoniae and enterobacter sp. 8 meningitis. the initial treatment, as a single agent, of menigitis in children and immunocompetent adults when presumed or proven to be caused by h.influenzae type b, n.meningitidis, strep.pneumoniae or enterobacteriaceae pending culture and sensitivity results. 9 surgical prophylaxis . the preoperarive administraion of a single 1g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical_procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. 10 susceptibility testing. before instituting treatement with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Canada - anglais - Health Canada

pfizer canada ulc - ceftriaxone (ceftriaxone sodium) - powder for solution - 2g - ceftriaxone (ceftriaxone sodium) 2g - third generation cephalosporins